Condition:   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Indacaterol dose A;   Drug: Indacaterol dose B;   Drug: Indacaterol dose C;   Drug: Indacaterol dose D;   Drug: Placebo;   Drug: Salmeterol
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Condition:   Asthma
Interventions:   Drug: Indacaterol dose;   Drug: Placebo;   Drug: Salmeterol
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Conditions:   Peripheral Vascular Disease;   Embolism and Thrombosis;   Venous Thrombosis
Intervention:  
Sponsor:   MEDRAD Interventional/Possis
Recruiting - verified March 2010

Condition:   Influenza
Interventions:   Drug: Oseltamivir;   Drug: Oseltamivir
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Conditions:   Pulmonary Disease, Chronic Obstructive;   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: FF Inhalation Powder;   Drug: FF/GW642444 Inhalation Powder;   Drug: GW642444 Inhalation Powder;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: aclidinium bromide;   Drug: aclidinium bromide
Sponsors:   Forest Laboratories;   Almirall, S.A.
Recruiting - verified February 2010

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: vinorelbine ditartrate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: FF/GW642444 Inhalation Powder;   Drug: GW642444 Inhalation Powder
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Combivent Respimat;   Drug: Combivent CFC-MDI;   Drug: Atrovent HFA + Albuterol HFA
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Acute Coronary Syndrome;   Atherosclerosis;   Cardiovascular Disease;   Coronary Heart Disease
Interventions:   Drug: Darapladib 160 mg;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Lymphoma;   Lymphoproliferative Disorder
Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
Recruiting - verified March 2010

Condition:   Coronary Artery Disease
Interventions:   Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent;   Drug: prasugrel;   Drug: placebo;   Drug: aspirin
Sponsors:   Boston Scientific Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.
Recruiting - verified March 2010

Conditions:   Osteoarthritis, Knee;   Osteoarthritis, Hip
Interventions:   Other: Tanezumab 2.5 mg;   Other: Tanezumab 5 mg;   Other: Tanezumab 10 mg
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Nonneoplastic Condition
Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Abatacept;   Drug: Adalimumab
Sponsor:   Bristol-Myers Squibb
Recruiting - verified December 2009

Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Genetic: loss of heterozygosity analysis;   Other: cytology specimen collection procedure;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Other: biologic sample preservation procedure;   Other: medical chart review
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Neoplasm of Uncertain Malignant Potential;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Other: cytology specimen collection procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Nonneoplastic Condition
Interventions:   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: arsenic trioxide;   Drug: cytarabine;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: tretinoin;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   HIV;   HIV Infections;   Pregnancy
Interventions:   Drug: TMC114 (darunavir);   Drug: TMC125 (etravirine);   Drug: TMC114r (ritonavir)
Sponsors:   Tibotec, Inc;   Tibotec Therapeutics, a Division of Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010

Conditions:   Impetigo;   Secondarily-infected Traumatic Lesions
Interventions:   Drug: Linezolid;   Drug: Retpamulin Ointment, 1%
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke University
Recruiting - verified October 2009

Conditions:   Adrenocortical Carcinoma;   Kidney Cancer;   Liver Cancer;   Neuroblastoma;   Retinoblastoma;   Sarcoma
Interventions:   Biological: cixutumumab;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Human Immunodeficiency Virus-1
Interventions:   Drug: maraviroc;   Drug: maraviroc
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   HIV-1
Interventions:   Drug: UK-453,061 Dose 1;   Drug: UK-453,061 Dose 2;   Drug: Etravirine
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   HIV-1
Interventions:   Other: Standard of care tests if needed;   Other: Standard of care tests if needed;   Other: Standard of care tests if needed;   Other: Standard of care tests if needed;   Other: Standard of care tests if needed;   Other: Standard of care tests if needed
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Lung Cancer
Interventions:   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Other: active surveillance
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Advanced Breast Cancer;   Breast Cancer
Interventions:   Drug: Neratinib;   Drug: Lapatinib plus Capecitabine
Sponsor:   Wyeth
Recruiting - verified February 2010

Conditions:   Brain and Central Nervous System Tumors;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Therapy-related Toxicity
Interventions:   Other: questionnaire administration;   Procedure: cognitive assessment;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Asthma
Interventions:   Drug: tiotropium 5mcg/day;   Drug: tiotropium 5mcg/day
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Pfizer
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Drug: cisplatin;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: zoledronic acid;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Liver Cancer;   Neuroblastoma;   Ototoxicity;   Ovarian Cancer;   Sarcoma
Interventions:   Drug: sodium thiosulfate;   Procedure: examination
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Clopidogrel;   Drug: Prasugrel;   Drug: Commercially-available Aspirin
Sponsors:   Eli Lilly and Company;   Daiichi Sankyo Co., Ltd.;   Duke University
Recruiting - verified March 2010

Condition:   Retinoblastoma
Interventions:   Genetic: DNA ploidy analysis;   Genetic: DNA stability analysis;   Genetic: Southern blotting;   Genetic: genetic linkage analysis;   Genetic: loss of heterozygosity analysis;   Genetic: mutation analysis;   Genetic: polymorphism analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: evaluation of cancer risk factors;   Procedure: mutation carrier screening
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: cixutumumab;   Drug: capecitabine;   Drug: lapatinib ditosylate
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Drug: cilengitide
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: bortezomib;   Drug: cytarabine;   Drug: etoposide phosphate;   Drug: idarubicin
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: Placebo;   Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor:   Hoffmann-La Roche
Recruiting - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: fluorouracil
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: lestaurtinib;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Retinoblastoma
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: thiotepa;   Drug: vincristine sulfate;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic bone marrow transplantation
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: topotecan hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Genetic: DNA ploidy analysis;   Genetic: chromosomal translocation analysis;   Genetic: fluorescence in situ hybridization;   Genetic: polymorphism analysis;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Venous Thrombosis;   Pulmonary Embolism
Interventions:   Drug: Apixaban;   Drug: Enoxaparin
Sponsor:   Bristol-Myers Squibb
Recruiting - verified February 2010

Conditions:   Cognitive/Functional Effects;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment
Interventions:   Genetic: microarray analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: cognitive assessment;   Procedure: diffusion tensor imaging;   Procedure: management of therapy complications;   Procedure: psychosocial assessment and care
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Atrial Fibrillation;   Atrial Flutter
Interventions:   Drug: warfarin;   Drug: apixaban
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: isotretinoin;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Bone Neoplasms;   Pain, Intractable;   Cancer
Interventions:   Drug: Pregabalin;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: gemtuzumab ozogamicin;   Drug: mitoxantrone hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Neurotoxicity;   Peripheral Neuropathy;   Sarcoma
Interventions:   Dietary Supplement: glutamic acid;   Other: placebo
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI);   Children's Oncology Group
Recruiting - verified February 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: thioguanine
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   HIV-1
Intervention:   Drug: TMC125
Sponsor:   Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Childhood Malignant Fibrous Histiocytoma of Bone;   Sarcoma
Interventions:   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Other: clinical observation;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Retinoblastoma
Interventions:   Drug: carboplatin;   Drug: etoposide;   Drug: vincristine sulfate;   Other: clinical observation
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: thiotepa;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Southwest Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: chemotherapy;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   American College of Surgeons;   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010

Condition:   Adrenocortical Carcinoma
Interventions:   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: mitotane;   Procedure: conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Behavioral: compliance monitoring;   Drug: mercaptopurine;   Drug: methotrexate;   Other: study of socioeconomic and demographic variables
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Metastatic Cancer;   Prostate Cancer
Interventions:   Drug: atrasentan hydrochloride;   Drug: docetaxel;   Drug: prednisone;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: PEG-interferon alfa-2b;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: methotrexate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Drug: CHOP regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: epratuzumab;   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: lomustine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Genetic: cytogenetic analysis;   Genetic: mutation analysis;   Genetic: polymorphism analysis;   Other: questionnaire administration
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Ovarian Cancer
Interventions:   Biological: bleomycin sulfate;   Drug: cisplatin;   Drug: etoposide;   Procedure: conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Biological: therapeutic immune globulin;   Other: clinical observation
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Biological: aldesleukin;   Biological: monoclonal antibody Ch14.18;   Biological: sargramostim;   Drug: isotretinoin
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: letrozole;   Other: placebo
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   International Breast Cancer Study Group;   Eastern Cooperative Oncology Group;   Southwest Oncology Group;   Cancer and Leukemia Group B;   European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009

Condition:   Melanoma (Skin)
Interventions:   Biological: recombinant interferon alfa;   Other: clinical observation
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   Children's Oncology Group
Recruiting - verified March 2010